The dangers of compounded bioidentical hormone replacement therapy
- PMID: 31672802
- PMCID: PMC6808563
- DOI: 10.3399/bjgp19X706169
The dangers of compounded bioidentical hormone replacement therapy
Comment on
-
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.JAMA. 2002 Jul 17;288(3):321-33. doi: 10.1001/jama.288.3.321. JAMA. 2002. PMID: 12117397 Clinical Trial.
References
-
- Slopien R, Wender-Ozegowska E, Rogowicz-Frontczak A, et al. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018;117:6–10. - PubMed
-
- The National Institute for Health and Care Excellence Menopause: diagnosis and management NG23. 2015. https://www.nice.org.uk/guidance/ng23 (accessed 23 Sep 2019) - PubMed
-
- Baber RJ, Panay N, Fenton A, IMS Writing Group 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150. - PubMed
-
- Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources